Fairmont Chateau Whistler Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2015
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD) (X8)
Organizer(s) Jay D. Horton, Douglas G. Mashek and Brian N. Finck
March 22—27, 2015
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Nov 20, 2014
Abstract Deadline: Dec 18, 2014
Scholarship Deadline: Nov 20, 2014
Discounted Registration Deadline: Jan 21, 2015
Sponsored by Intercept Pharmaceuticals, Inc., Merck & Co., Inc., Regeneron Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited
Summary of Meeting:
Abnormalities in hepatic intermediary metabolism are common in obesity and are a significant source of morbidity and mortality in obese people. For example, nonalcoholic fatty liver disease (NAFLD) affects over 25% of the US population and has become the most common cause of liver failure and transplantation. NAFLD is also linked to the development of major metabolic diseases such as type 2 diabetes and cardiovascular diseases. Despite the central role of the liver in whole-body energy metabolism and its contribution to disease development, there are literally no dedicated meetings that focus on the cellular and mechanistic aspects of the regulation of liver metabolism. This meeting will bring together experts, both basic scientists and clinicians, across diverse fields including biochemistry, cell biology, genetics, hepatology, nutrition, physiology and virology to exclusively focus on the liver and bridge a translational divide. Meeting themes will center on regulation of hepatic energy metabolism, crosstalk between the liver and different organs and cell types and how alterations in macronutrient metabolism contribute to disease etiology. The objectives of this conference are to: 1) Expose scientists across diverse disciplines to different aspects of hepatic metabolism and NAFLD development; 2) Find synergies in research efforts to expedite our understanding of hepatic energy metabolism; and 3) Explore emerging metabolic targets for therapeutic interventions to prevent or alleviate NAFLD and related comorbidities.
View Scholarships/Awards
Abnormalities in hepatic intermediary metabolism are common in obesity and are a significant source of morbidity and mortality in obese people. For example, nonalcoholic fatty liver disease (NAFLD) affects over 25% of the US population and has become the most common cause of liver failure and transplantation. NAFLD is also linked to the development of major metabolic diseases such as type 2 diabetes and cardiovascular diseases. Despite the central role of the liver in whole-body energy metabolism and its contribution to disease development, there are literally no dedicated meetings that focus on the cellular and mechanistic aspects of the regulation of liver metabolism. This meeting will bring together experts, both basic scientists and clinicians, across diverse fields including biochemistry, cell biology, genetics, hepatology, nutrition, physiology and virology to exclusively focus on the liver and bridge a translational divide. Meeting themes will center on regulation of hepatic energy metabolism, crosstalk between the liver and different organs and cell types and how alterations in macronutrient metabolism contribute to disease etiology. The objectives of this conference are to: 1) Expose scientists across diverse disciplines to different aspects of hepatic metabolism and NAFLD development; 2) Find synergies in research efforts to expedite our understanding of hepatic energy metabolism; and 3) Explore emerging metabolic targets for therapeutic interventions to prevent or alleviate NAFLD and related comorbidities.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 22
MONDAY, MARCH 23
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
TUESDAY, MARCH 24
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
WEDNESDAY, MARCH 25
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
THURSDAY, MARCH 26
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
FRIDAY, MARCH 27
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MARCH 22
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Jay D. Horton,
University of Texas Southwestern Medical Center, USA
Randal J. Kaufman,
Sanford-Burnham Medical Research Institute, USA
ER Stress in NAFLD and Its Progression to NASH
ER Stress in NAFLD and Its Progression to NASH
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
08:00—09:00
Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Johan Auwerx,
École Polytechnique Fédérale de Lausanne, Switzerland
Jodi Nunnari,
University of California, Davis, USA
Molecular Mechanisms of Mitochondrial Behavior
Molecular Mechanisms of Mitochondrial Behavior
09:00—11:15
Hepatic Flux in NAFLD
Meeting has ended...abstracts no longer viewable online.
*
Jay D. Horton,
University of Texas Southwestern Medical Center, USA
Shawn C. Burgess,
University of Texas Southwestern Medical Center, USA
Obesity’s Beast of Burden
Obesity’s Beast of Burden
Brian N. Finck,
Washington University School of Medicine, USA
New Pathways for Targeting Metabolic Disease and Hepatic Steatosis
New Pathways for Targeting Metabolic Disease and Hepatic Steatosis
Eric B. Taylor,
University of Iowa, USA
Regulation of Hepatic Gluconeogenesis by Mitochondrial Pyruvate Carrier 1
Regulation of Hepatic Gluconeogenesis by Mitochondrial Pyruvate Carrier 1
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
09:00—11:15
Mitochondrial Function and Morphology and the Metabolic Syndrome
Meeting has ended...abstracts no longer viewable online.
*
Andrew G. Dillin,
University of California, Berkeley, USA
Orian S. Shirihai,
University of California, Los Angeles, USA
Mitochondrial Fission/Fusion and Pancreatic Function
Mitochondrial Fission/Fusion and Pancreatic Function
Johan Auwerx,
École Polytechnique Fédérale de Lausanne, Switzerland
Mitonuclear Protein Balance as a Determinant of Health- and Lifespan
Mitonuclear Protein Balance as a Determinant of Health- and Lifespan
17:00—19:00
Liver Metabolism in Human Health and Disease
Meeting has ended...abstracts no longer viewable online.
*
Samuel Klein,
Washington University School of Medicine, USA
Metabolic Implications of NAFLD in Obesity
Metabolic Implications of NAFLD in Obesity
Hannele Yki-Järvinen,
University of Helsinki, Finland
NAFLD and Hepatic Insulin Resistance in the Human Liver
NAFLD and Hepatic Insulin Resistance in the Human Liver
Michael Roden,
Universitätsklinikum Düsseldorf, Germany
Quantifying Hepatic Energetics in Health and Disease
Quantifying Hepatic Energetics in Health and Disease
Elizabeth K. Speliotes,
University of Michigan, USA
Short Talk: Genetic Variation in FXR/RXR Pathway Genes that Play a Role in Bile Acid, Cholesterol, Lipid and Carbohydrate Metabolism Predispose to Nonalcoholic Fatty Liver Disease in Humans
Short Talk: Genetic Variation in FXR/RXR Pathway Genes that Play a Role in Bile Acid, Cholesterol, Lipid and Carbohydrate Metabolism Predispose to Nonalcoholic Fatty Liver Disease in Humans
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
17:00—19:00
Quality Control in Mitochondria and the Metabolic Syndrome
Meeting has ended...abstracts no longer viewable online.
*
Jodi Nunnari,
University of California, Davis, USA
Thomas Langer,
CECAD Research Center, Germany
Mitochondrial Proteolysis and Metabolic Control
Mitochondrial Proteolysis and Metabolic Control
Andrew G. Dillin,
University of California, Berkeley, USA
Ablation of Olfactory Sensory Neurons Reprograms Peripheral Metabolism
Ablation of Olfactory Sensory Neurons Reprograms Peripheral Metabolism
Jonathan R. Friedman,
University of California, Davis, USA
Short Talk: MICOS, Respiratory Complexes and Mitochondrial Lipids Coordinately Build a Functional Mitochondrial Inner Membrane
Short Talk: MICOS, Respiratory Complexes and Mitochondrial Lipids Coordinately Build a Functional Mitochondrial Inner Membrane
Benjamin D. Stein,
The Salk Institute for Biological Studies, USA
Short Talk: Quantitative Proteomics Screen Using Stable Isotope Labeling in Mammals Identifies Novel AMPK Substrates in Mouse Liver
Short Talk: Quantitative Proteomics Screen Using Stable Isotope Labeling in Mammals Identifies Novel AMPK Substrates in Mouse Liver
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Gastrointestinal Lipid Signaling and the Metabolic Syndrome (Joint)
Meeting has ended...abstracts no longer viewable online.
*
Anu Suomalainen Wartiovaara,
University of Helsinki, Finland
Kristina Schoonjans,
École Polytechnique Fédérale de Lausanne – EPFL, Switzerland
The Bile Acid Receptor TGR5 at the Crossroads of Inflammation and Metabolism
The Bile Acid Receptor TGR5 at the Crossroads of Inflammation and Metabolism
Eleftheria Maratos-Flier,
Beth Israel Deaconess Medical Center, USA
New Insights into NAFLD: Fructose, Fat and FGF21
New Insights into NAFLD: Fructose, Fat and FGF21
David D. Moore,
Baylor College of Medicine, USA
FXR as an Integrator of the Fed State in the Liver
FXR as an Integrator of the Fed State in the Liver
Junichiro Sonoda,
Regeneron Pharmaceuticals, Inc., USA
Stimulating Brown Fat with a Therapeutic Antibody
Stimulating Brown Fat with a Therapeutic Antibody
Allyson N. Hamlin,
University of Cincinnati, USA
Short Talk: Hepatic LRP1 Deficiency Exacerbates Microsteatosis and Hepatocyte Cell Death via Lysosomal Insufficiency
Short Talk: Hepatic LRP1 Deficiency Exacerbates Microsteatosis and Hepatocyte Cell Death via Lysosomal Insufficiency
14:30—16:30
Workshop 1: Junior Investigator Forum
*
Peter A. Crawford,
University of Minnesota, USA
William S. Baldwin,
Clemson University, USA
Gender Differences in Response to a High-Fat Diet in CYP3A-null Mice
Gender Differences in Response to a High-Fat Diet in CYP3A-null Mice
Guenter Haemmerle,
University of Graz, Austria
Adipose Tissue Lipolysis Regulates G0S2 and FGF21 Expression in the Liver
Adipose Tissue Lipolysis Regulates G0S2 and FGF21 Expression in the Liver
Athan Kuliopulos,
Oasis Pharmaceuticals, USA
Protease-Activated Receptor-2 (PAR2)–A Novel Therapeutic Target in Nonalcoholic Steatohepatitis (NASH)
Protease-Activated Receptor-2 (PAR2)–A Novel Therapeutic Target in Nonalcoholic Steatohepatitis (NASH)
Suresh T. Mathews,
Auburn University, USA
AICAR Downregulates High Glucose-Induced Expression of Fetuin-A through AMPK-p38MAPK Axis in HepG2 Cells
AICAR Downregulates High Glucose-Induced Expression of Fetuin-A through AMPK-p38MAPK Axis in HepG2 Cells
James Xiaojun Rong,
Lilly China Research & Development Center, China
Knockdown of Na+-Coupled Citrate Transporter Slc13a5 in Liver Decreased Body Weight and Improved Insulin Sensitivity in Mice with Pre-Existing Obese, Hyperglycemic Conditions
Knockdown of Na+-Coupled Citrate Transporter Slc13a5 in Liver Decreased Body Weight and Improved Insulin Sensitivity in Mice with Pre-Existing Obese, Hyperglycemic Conditions
Takuya F. Sakaguchi,
Cleveland Clinic, USA
Gain-of-Function Mutation in cmklr1, a Chemerin Receptor, Leads to Hepatic Steatosis and Inflammation in Zebrafish
Gain-of-Function Mutation in cmklr1, a Chemerin Receptor, Leads to Hepatic Steatosis and Inflammation in Zebrafish
Daniel F. Vatner,
Yale University School of Medicine, USA
Substrate-Dependent Insulin-Independent Regulation of Hepatic Fatty Acid Esterification
Substrate-Dependent Insulin-Independent Regulation of Hepatic Fatty Acid Esterification
Jim Perfield,
Eli Lilly and Company, USA
Insight into the PPAR alpha-Dependent and –Independent Regulation of FGF21
Insight into the PPAR alpha-Dependent and –Independent Regulation of FGF21
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
14:30—16:30
Workshop 1: Mitochondria and Muscle
*
Reuben J. Shaw,
The Salk Institute for Biological Studies, USA
Thomas Philip Agnew,
University of Oxford, UK
oboe – A Novel Mouse Model of Mitochondrial Disease with Reduced Adiposity and Hypertrophic Cardiomyopathy
oboe – A Novel Mouse Model of Mitochondrial Disease with Reduced Adiposity and Hypertrophic Cardiomyopathy
Weiwei Fan,
The Salk Institute for Biological Studies, USA
Ppardelta-Mediated Shift in Muscle Mitochondrial Substrate Boosts Energy Expenditure and Attenuates Diet-Induced Obesity
Ppardelta-Mediated Shift in Muscle Mitochondrial Substrate Boosts Energy Expenditure and Attenuates Diet-Induced Obesity
David E. Cohen,
Brigham and Women's Hospital, Harvard Medical School, USA
Thioesterase Superfamily Member 2 (Them2) Channels Fatty Acids to Glycerol-3-Phosphate Acyltransferase-1 (GPAT1): Role in Hepatic Insulin Resistance
Thioesterase Superfamily Member 2 (Them2) Channels Fatty Acids to Glycerol-3-Phosphate Acyltransferase-1 (GPAT1): Role in Hepatic Insulin Resistance
Takashi Nakagawa,
University of Toyama, Japan
NAD Synthesis Enzyme, Nmnat3 Protects against High Fat Diet- and Age-Induced Obesity in Mice
NAD Synthesis Enzyme, Nmnat3 Protects against High Fat Diet- and Age-Induced Obesity in Mice
Eric S. Muise,
Merck & Co., Inc., USA
Acute Treatment of Mice with Potent AMPK Activators Mimics Acute Exercise-Induced Transcriptional Effects in Skeletal Muscle
Acute Treatment of Mice with Potent AMPK Activators Mimics Acute Exercise-Induced Transcriptional Effects in Skeletal Muscle
Mario Ost,
German Institute of Human Nutrition, Germany
Muscle Mitohormesis Promotes Cellular Survival via Serine/Glycine Pathway Flux
Muscle Mitohormesis Promotes Cellular Survival via Serine/Glycine Pathway Flux
Erin Quan Toyama,
Genomics Institute of the Novartis Research Foundation, USA
AMPK Regulation of Mitochondrial Dynamics
AMPK Regulation of Mitochondrial Dynamics
17:00—19:00
Pathways to NASH, Fibrosis and Hepatocullular Carcinoma
Meeting has ended...abstracts no longer viewable online.
*
Brent A. Tetri,
St. Louis University, USA
Anna Mae Diehl,
Duke University, USA
Hedgehog Signaling and Hepatic Fibrosis
Hedgehog Signaling and Hepatic Fibrosis
Gyongyi Szabo,
University of Massachusetts Medical School, USA
Metabolic Danger Signals in Immune Cell and Hepatocyte Crosstalk in NASH
Metabolic Danger Signals in Immune Cell and Hepatocyte Crosstalk in NASH
Roger J. Davis,
HHMI/University of Massachusetts Medical School, USA
Metabolic Stress Signaling Mediated by JNK
Metabolic Stress Signaling Mediated by JNK
Maria E. Moreno-Fernandez,
Cincinnati Children's Hospital, USA
Short Talk: Role of the IL-17 Axis in the Progression of Non-Alcoholic Fatty Liver Disease
Short Talk: Role of the IL-17 Axis in the Progression of Non-Alcoholic Fatty Liver Disease
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
17:00—19:00
The Metabolic Syndrome: Insights from Rare Mitochondrial Diseases
Meeting has ended...abstracts no longer viewable online.
*
Sadaf Farooqi,
University of Cambridge, UK
Anu Suomalainen Wartiovaara,
University of Helsinki, Finland
Mitochondrial Dysfunction Modifies Nutrient Metabolism – Implications to Disease
Mitochondrial Dysfunction Modifies Nutrient Metabolism – Implications to Disease
David Rand,
Brown University, USA
Mitonuclear Genetic Interactions in Drosophila Aging and Disease
Mitonuclear Genetic Interactions in Drosophila Aging and Disease
Douglas C. Wallace,
Children's Hospital of Philadelphia, USA
A Mitochondrial Diseases – The Paradigms
A Mitochondrial Diseases – The Paradigms
Iliana A. Chatzispyrou,
Academic Medical Centre, Netherlands
Short Talk: Identification of a Novel Mutation for Perrault Syndrome in the Mitochondrial rRNA Chaperone ERAL1
Short Talk: Identification of a Novel Mutation for Perrault Syndrome in the Mitochondrial rRNA Chaperone ERAL1
08:00—11:00
Extra-Hepatic Regulation of Liver Metabolism
Meeting has ended...abstracts no longer viewable online.
*
Rosalind A. Coleman,
University of North Carolina at Chapel Hill, USA
Jens C. Brüning,
Max Planck Institute for Metabolism Research, Germany
Role of Distinct Ceramide Species in Obesity-Associated Insulin Resistance
Role of Distinct Ceramide Species in Obesity-Associated Insulin Resistance
Frank J. Gonzalez,
National Institutes of Health, USA
The Gut Microbiota Influences NAFLD thorough Intestinal FXR Signaling
The Gut Microbiota Influences NAFLD thorough Intestinal FXR Signaling
George N. Ioannou,
University of Washington, USA
Role of Cholesterol in the Progression of Steatosis to NASH
Role of Cholesterol in the Progression of Steatosis to NASH
Steven A. Kliewer,
University of Texas Southwestern Medical Center, USA
Metabolic FGFs 15/19 and 21: From Physiology to Pharmacology
Metabolic FGFs 15/19 and 21: From Physiology to Pharmacology
Mattias Bergentall,
Gothenburg University, Sweden
Short Talk: The Gut Microbiota Modulates Sucrose-Induced NAFLD
Short Talk: The Gut Microbiota Modulates Sucrose-Induced NAFLD
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
08:00—11:00
Genetics of the Metabolic Syndrome
Meeting has ended...abstracts no longer viewable online.
*
David Rand,
Brown University, USA
Norbert Perrimon,
Harvard Medical School, USA
Discovery of in vivo Regulators of Glucagon-Induced Hyperglycemia
Discovery of in vivo Regulators of Glucagon-Induced Hyperglycemia
Jose Antonio Enríquez,
Centro Nacional de Investigaciones, Spain
Talk Title to be Announced
Talk Title to be Announced
Chris Day,
Newcastle University, UK
Genetic of NAFLD
Genetic of NAFLD
14:30—16:30
Workshop 2: NAFLD Therapeutics
*
Henry N. Ginsberg,
Columbia University College of Physicians and Surgeons, USA
Michael L. Chouinard,
Eli Lilly and Company, USA
Established Therapies for Diabetes and Dyslipidemia Aimed at CYP7A1 Induction Are Vulnerable to FXR Modulation by Nutrient Fat, Perhaps Limiting their Use in Non-alcoholic Steatohepatitis (NASH)
Established Therapies for Diabetes and Dyslipidemia Aimed at CYP7A1 Induction Are Vulnerable to FXR Modulation by Nutrient Fat, Perhaps Limiting their Use in Non-alcoholic Steatohepatitis (NASH)
Derek M. Erion,
Takeda, USA
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM Mouse Model of NASH
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM Mouse Model of NASH
Tadasuke Komori,
Wakayama Medical University, Japan
The Roles of Oncostatin M in the Treatment of Nonalcoholic Fatty Liver Disease in Mice
The Roles of Oncostatin M in the Treatment of Nonalcoholic Fatty Liver Disease in Mice
Xiaoxin Wang,
University of Colorado Denver, USA
Treatment with the FXR-TGR5 Dual Agonist INT-767 Decreases NAFLD-NASH in Mice Fed a Western Diet
Treatment with the FXR-TGR5 Dual Agonist INT-767 Decreases NAFLD-NASH in Mice Fed a Western Diet
Eyal Breitbart,
VBL Therapeutics, Israel
TLR4 Complex Antagonist Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
TLR4 Complex Antagonist Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Narayanan Hariharan,
Tekmira Pharmaceuticals, Canada
Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia
Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia
Moshe Levi,
Georgetown University, USA
Bile Acid Sequestrant Prevents NAFLD/NASH in Diet-Induced Obesity and Insulin Resistant Mice
Bile Acid Sequestrant Prevents NAFLD/NASH in Diet-Induced Obesity and Insulin Resistant Mice
Mukul R. Jain,
Zydus Research Centre, India
Efficacy of Saroglitazar, a Novel PPAR alpha/gamma Agonist in a Mouse Model of Non-Alcoholic Steatohepatitis
Efficacy of Saroglitazar, a Novel PPAR alpha/gamma Agonist in a Mouse Model of Non-Alcoholic Steatohepatitis
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
14:30—16:30
Workshop 2: Disease Mechanism and Therapy
*
Junichiro Sonoda,
Regeneron Pharmaceuticals, Inc., USA
Laurent Mouchiroud,
École Polytechnique Federale de Lausanne – EPFL, Switzerland
Urolithin A Improves Fitness and Lifespan through Mitophagy
Urolithin A Improves Fitness and Lifespan through Mitophagy
Kevin G. Becker,
NIA, National Institutes of Health, USA
The Effects of Tomatidine on Three Cell Models of Differentiation
The Effects of Tomatidine on Three Cell Models of Differentiation
Elizabeth K. Speliotes,
University of Michigan, USA
Human Genetic Variants In or Near Mitochondrial Genes Uncouple Obesity from Metabolic Disease
Human Genetic Variants In or Near Mitochondrial Genes Uncouple Obesity from Metabolic Disease
Andrea Galmozzi,
The Scripps Research Institute, USA
ThermoMouse: An in vivo Model to Identify Modulators of UCP1 Expression in Brown Adipose Tissue
ThermoMouse: An in vivo Model to Identify Modulators of UCP1 Expression in Brown Adipose Tissue
Ambar Grijalva,
Columbia University, USA
Lipid Accumulation in Adipose Tissue Macrophages Reveals a Non-Classical Regulated Pathway of Lipid Release in Adipocytes
Lipid Accumulation in Adipose Tissue Macrophages Reveals a Non-Classical Regulated Pathway of Lipid Release in Adipocytes
Stefan G. Kauschke,
Boehringer Ingelheim Pharma, Germany
Evaluation of BACE2 Inhibitors to Delay Progression of beta-Cell Failure in T2DM
Evaluation of BACE2 Inhibitors to Delay Progression of beta-Cell Failure in T2DM
Yael Kuperman,
Weizmann Institute, Israel
CRFR1 Inhibits AgRP Neurons to Allow Appropriate Sympathetic Nervous System Activity following Challenge
CRFR1 Inhibits AgRP Neurons to Allow Appropriate Sympathetic Nervous System Activity following Challenge
17:00—19:00
Regulatory Nodes of Hepatic Energy Metabolism
Meeting has ended...abstracts no longer viewable online.
*
Douglas G. Mashek,
University of Minnesota, USA
Reuben J. Shaw,
The Salk Institute for Biological Studies, USA
AMPK: Central Integrator of Metabolic Adaptation and Mitochondrial Homeostasis
AMPK: Central Integrator of Metabolic Adaptation and Mitochondrial Homeostasis
Anders M. Näär,
University of California, Berkeley, USA
Peter A. Crawford,
University of Minnesota, USA
Ketone Metabolism and Hepatic Energy Homeostasis in the Absorptive State
Ketone Metabolism and Hepatic Energy Homeostasis in the Absorptive State
Geula Hanin,
Hebrew University, Israel
Short Talk: MicroRNA-132 Is a Reversible Amplifier of Hepatic Lipid Accumulation
Short Talk: MicroRNA-132 Is a Reversible Amplifier of Hepatic Lipid Accumulation
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
17:00—19:00
Therapy of the Metabolic Syndrome
Meeting has ended...abstracts no longer viewable online.
*
Ajay Chawla,
University of California, San Francisco, USA
Matthias H. Tschöp,
Helmholtz Zentrum München and Technische Universität München, Germany
Novel Poly-Pharmacy for the Treatment of Obesity and Diabetes
Novel Poly-Pharmacy for the Treatment of Obesity and Diabetes
Patrick R. Griffin,
The Scripps Research Institute, USA
Pharmacological Repression of PPARG Improves Metabolic Parameters and Promotes Osteogenesis
Pharmacological Repression of PPARG Improves Metabolic Parameters and Promotes Osteogenesis
Saswata Talukdar,
Merck Sharp & Dohme, USA
Chronic Administration of a Long-Acting FGF21 Molecule PF-05231023 Decreases Body Weight and Improves Metabolic Profile in Non-Human Primates and Subjects with Type 2 Diabetes
Chronic Administration of a Long-Acting FGF21 Molecule PF-05231023 Decreases Body Weight and Improves Metabolic Profile in Non-Human Primates and Subjects with Type 2 Diabetes
Riekelt H. Houtkooper,
Academic Medical Center, Netherlands
Short Talk: Tetracycline-Dependent Mitochondrial Dysfunction Confounds Research and Poses an Environmental Hazard
Short Talk: Tetracycline-Dependent Mitochondrial Dysfunction Confounds Research and Poses an Environmental Hazard
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
TAG Synthesis and Turnover
Meeting has ended...abstracts no longer viewable online.
*
Brian N. Finck,
Washington University School of Medicine, USA
Rosalind A. Coleman,
University of North Carolina at Chapel Hill, USA
Hepatic Lipid Synthesis and Insulin Resistance
Hepatic Lipid Synthesis and Insulin Resistance
Douglas G. Mashek,
University of Minnesota, USA
TAG Hydrolysis as a Branch Point in Hepatic Metabolism
TAG Hydrolysis as a Branch Point in Hepatic Metabolism
Robert V. Farese Jr.,
Harvard School of Public Health, USA
Mechanisms and Consequences of Lipid Storage
Mechanisms and Consequences of Lipid Storage
Elizabeth J. Parks,
University of Missouri, USA
In vivo Quantitation of Intracellular TAG Assembly in Humans
In vivo Quantitation of Intracellular TAG Assembly in Humans
Ryan J. Schulze,
Mayo Clinic, USA
Short Talk: Small GTPases as Regulators of Hepatocellular Lipophagy
Short Talk: Small GTPases as Regulators of Hepatocellular Lipophagy
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
08:00—11:00
Metabolic Inflammation, Mitochondria and Metabolic Disease
Meeting has ended...abstracts no longer viewable online.
*
Juleen R. Zierath,
Karolinska Institutet, Sweden
Ajay Chawla,
University of California, San Francisco, USA
Innate Control of Metabolism
Innate Control of Metabolism
Takashi Kadowaki,
University of Tokyo, Japan
Adiponectin Receptor and Metabolic Syndrome: Pathophysiology and Therapeutic Strategy
Adiponectin Receptor and Metabolic Syndrome: Pathophysiology and Therapeutic Strategy
Anthony W. Ferrante,
Columbia University, USA
Immune Regulation of Systemic Metabolism
Immune Regulation of Systemic Metabolism
Keir J. Menzies,
University of Ottawa, Canada
Short Talk: NAD+ Repletion Improves the Mdx Mouse Muscle Phenotype by Countering Increased Levels of PARylation
Short Talk: NAD+ Repletion Improves the Mdx Mouse Muscle Phenotype by Countering Increased Levels of PARylation
Rudolf J. Wiesner,
University of Cologne, Germany
Short Talk: Inhibition of Mitochondrial Complex I by Metformin Induces a Futile Lactate Cycle, which Increases Energy Expenditure and Slows Down Development of Type 2 Diabetes (T2DM)
Short Talk: Inhibition of Mitochondrial Complex I by Metformin Induces a Futile Lactate Cycle, which Increases Energy Expenditure and Slows Down Development of Type 2 Diabetes (T2DM)
17:00—18:45
Hepatic Metabolic Alterations Associated with NAFLD
Meeting has ended...abstracts no longer viewable online.
*
Jay D. Horton,
University of Texas Southwestern Medical Center, USA
Jay D. Horton,
University of Texas Southwestern Medical Center, USA
Molecular Mediators of Nonalcoholic Fatty Liver Disease
Molecular Mediators of Nonalcoholic Fatty Liver Disease
Mark A. Herman,
Duke University Medical Center, USA
ChREBP Isoforms Link Glucose and Lipid Metabolism
ChREBP Isoforms Link Glucose and Lipid Metabolism
Henry N. Ginsberg,
Columbia University College of Physicians and Surgeons, USA
Role of Autophagy in Hepatic Lipid Homeostasis
Role of Autophagy in Hepatic Lipid Homeostasis
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
17:00—18:45
Metabolic Syndrome and Muscle Energy Homeostasis
Meeting has ended...abstracts no longer viewable online.
*
David D. Moore,
Baylor College of Medicine, USA
Julie St-Pierre,
McGill University, Canada
Modulation of Mitochondrial Metabolism and Cellular Bioenergetics
Modulation of Mitochondrial Metabolism and Cellular Bioenergetics
Juleen R. Zierath,
Karolinska Institutet, Sweden
Altered DNA Methylation of Glycolytic and Lipogenic Genes in Skeletal Muscle and Liver from Obese and Type 2 Diabetic Patients
Altered DNA Methylation of Glycolytic and Lipogenic Genes in Skeletal Muscle and Liver from Obese and Type 2 Diabetic Patients
Satchidananda Panda,
The Salk Institute for Biological Studies, USA
Eating Pattern and Metabolic Diseases
Eating Pattern and Metabolic Diseases
18:45—19:00
Meeting Wrap Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
Following Session is for Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)
18:45—19:00
Meeting Wrap Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
